The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, open-label, single-arm, phase II trial to evaluate the efficacy and safety of geptanolimab (GB226) in the treatment of patients (pts) with programmed cell death ligand 1 (PD-L1)–positive recurrent or metastatic cervical cancer, for whom prior platinum-containing chemotherapy has failed.
 
Jusheng An
No Relationships to Disclose
 
Yunyan Zhang
No Relationships to Disclose
 
Mei Feng
No Relationships to Disclose
 
Keqiang Zhang
No Relationships to Disclose
 
Jianqing Zhu
No Relationships to Disclose
 
Aiqin He
No Relationships to Disclose
 
Xiumin Li
No Relationships to Disclose
 
Jin Peng
No Relationships to Disclose
 
Xinwen Wang
No Relationships to Disclose
 
Hongping Zhang
No Relationships to Disclose
 
Weimin Kong
No Relationships to Disclose
 
Guiling Li
No Relationships to Disclose
 
Jianlin Yuan
No Relationships to Disclose
 
Shiying Yu
No Relationships to Disclose
 
Hu Liu
No Relationships to Disclose
 
Cailing Ma
No Relationships to Disclose
 
Hongmin Chen
No Relationships to Disclose
 
Liangfang Shen
No Relationships to Disclose
 
Fan Xie
Employment - Genor BioPharma
Stock and Other Ownership Interests - Genor BioPharma
 
Lingying Wu
No Relationships to Disclose